Skip to main content
MANNKIND CORP logo

MANNKIND CORP — Investor Relations & Filings

Ticker · MNKD ISIN · US56400P7069 LEI · 213800GFBCNY1ZFST722 US Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2013-11-04 Capital/Financing Update
Country US United States of America
Listing US MNKD

About MANNKIND CORP

https://mannkindcorp.com/

MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products and devices. The company specializes in inhaled therapies for patients with cardiometabolic and orphan lung diseases. Its portfolio includes Afrezza®, an inhaled insulin for diabetes, and Tyvaso DPI®, a dry powder inhaler for pulmonary hypertension developed in collaboration with United Therapeutics. Through its acquisition of scPharmaceuticals, MannKind also markets FUROSCIX®, a subcutaneous treatment for edema in adults with chronic heart failure. The company's pipeline is focused on expanding indications for its existing products, including a pediatric application for Afrezza.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a promissory note, changes in borrowing terms, and issuance of shares upon warrant exercise. There are no financial statements or detailed financial performance data included. The document is focused on a capital structure update and financing agreement amendment. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about financing changes, not just an announcement of a report, so it is not an RPA or RNS. Hence, the classification is CAP with high confidence.
2013-11-04 English
MANNKIND CORPORATION 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content describes an announcement regarding the FDA's acknowledgment of the resubmission of a New Drug Application (NDA) for a product, including a press release attached as an exhibit. There are no financial statements or detailed financial data included, and the document is relatively short (2933 characters). It is primarily an announcement of a regulatory event and a press release, not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-10-30 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The content describes the resubmission of a new drug application (NDA) to the FDA and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, and the document is relatively short (2945 characters). It is primarily an announcement of an event rather than a full financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2013-10-16 English
POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3
Capital/Financing Update Classification · 95% confidence The document is a Post Effective Amendment No. 1 to Form S-3 filed with the SEC, which is a registration statement related to the resale of shares upon conversion of convertible notes. It includes a prospectus summary, risk factors, use of proceeds, and details about the offering and selling stockholders. The document is a regulatory filing related to securities registration and resale, not a financial report, earnings release, or management discussion. It is not a report itself but a registration statement amendment for capital raising purposes. Therefore, it fits best under Capital/Financing Update (CAP). The document length and content confirm it is a substantive filing, not a brief announcement or certification.
2013-09-18 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the creation of a direct financial obligation through a Facility Agreement involving convertible notes and unregistered sales of equity securities. It includes details about financing activities and related agreements. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a report publication announcement or a certification but a regulatory filing disclosing a material event related to capital raising. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6102 characters) supports it being a substantive filing rather than a brief announcement.
2013-09-06 English
FORM 4 SUBMISSION
Director's Dealing
2013-08-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.